iatroX logo
brainstormaskiatroXquizcpdknowledge centrehow it worksaboutblog
Knowledge Centre / Stevens-Johnson Syndrome (SJS) / Toxic Epidermal Necrolysis (TEN)

Stevens-Johnson Syndrome (SJS) / Toxic Epidermal Necrolysis (TEN)

Recognition and management of severe cutaneous adverse reactions.

Reviewed by Dr Kola Tytler MBBS CertHE MBA MRCGP (General Practitioner)
Last reviewed: 30 August 2025
DermatologyEmergency Medicine

Clinical Guidelines

British Association of Dermatologists guidelines for the management of Stevens–Johnson syndrome and toxic epidermal necrolysis
National
UK guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis 2016
National
UK guidelines for the management of Stevens–Johnson syndrome and toxic epidermal necrolysis
National

Recent iatroX Q&As

  • What are the key clinical features that differentiate Stevens-Johnson Syndrome (SJS) from Toxic Epidermal Necrolysis (TEN)?Updated: 8/16/2025
  • What criteria should I use to determine whether to refer a patient with SJS/TEN to secondary care?Updated: 8/16/2025
  • Which medications are commonly associated with the development of SJS/TEN that I should be aware of during patient assessments?Updated: 8/16/2025
  • What supportive care measures should be implemented for a patient diagnosed with SJS/TEN in a general practice environment?Updated: 8/16/2025
ask iatroX
privacy terms faq
UKCA Mark

iatroX is a UKCA-marked, MHRA-registered medical device.

Download on the App StoreGet it on Google Play